Palvella Therapeutics (PVLA) Return on Capital Employed (2014 - 2026)
Palvella Therapeutics (PVLA) reported Return on Capital Employed of 10.32% for Q1 2026, up 1667.0% year-over-year from 0.58% in Q1 2025, and up 38.85% quarter-over-quarter from 16.88% in Q4 2025.
Palvella Therapeutics (PVLA) Return on Capital Employed (2014 - 2026) Analysis & Trends
Palvella Therapeutics (PVLA) has 13 years of Return on Capital Employed data on file, last reported at 10.32% in Q1 2026.
- Return on Capital Employed for Q1 2026 came in at 10.32%, up 1667.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 10.32% (up 1667.0% YoY), and the FY2025 annual result was 14.0%, up 2531.0% from the prior year.
- Return on Capital Employed advanced to 10.32% in Q1 2026 per PVLA's latest filing, from 16.88% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 19.73% in Q3 2024 and troughed at 103.19% in Q1 2023.
- A 5-year average of 38.95% and a median of 38.9% in 2023 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2024 and 2025: Return on Capital Employed jumped 12032 bps in 2024, then slumped 7248 bps in 2025.
- A 5-year view of Return on Capital Employed shows it stood at 58.67% in 2022, then surged by 35 bps to 38.16% in 2023, then gained by 13 bps to 33.29% in 2024, then surged by 49 bps to 16.88% in 2025, then surged by 39 bps to 10.32% in 2026.
- Business Quant data shows PVLA's Return on Capital Employed at 10.32% in Q1 2026, 16.88% in Q4 2025, and 52.75% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 450.31% |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 51.73% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -107.40% |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -50.43% |
| 10 | Palvella Therapeutics | 1.49 Bn | 1.23 Bn | - | -10.32% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -10.32% |
| Dec 31, 2025 | -16.88% |
| Sep 30, 2025 | -52.75% |
| Jun 30, 2025 | -39.64% |
| Mar 31, 2025 | -27.00% |
| Dec 31, 2024 | -33.29% |
| Sep 30, 2024 | 19.73% |
| Jun 30, 2024 | -14.76% |
| Mar 31, 2024 | 17.13% |
| Dec 31, 2023 | -38.16% |
| Sep 30, 2023 | -83.92% |
| Jun 30, 2023 | -75.09% |
| Mar 31, 2023 | -103.19% |
| Sep 30, 2022 | -58.67% |
| Jun 30, 2022 | -55.23% |
| Mar 31, 2022 | -51.23% |
| Dec 31, 2021 | -47.85% |
| Sep 30, 2021 | -48.44% |
| Jun 30, 2021 | -51.63% |
| Mar 31, 2021 | -43.83% |